Gossamer Bio is trading at $10.27, up 5.07%, with biotech-sector strength offering a possible tailwind; no company-specific catalyst is confirmed for the October 28 move.
- The biotech sector is up 2.18%, while major indexes are only modestly higher.
- The latest company release listed is its September 23 seralutinib NDA submission.
- An earlier pre-market report noted a 5.3% decline with no confirmed overnight catalyst; the current move reverses that weakness.